Please select the option that best describes you:
Do you send Oncotype or Mammaprint as a predictive tool for patients with high grade (3/3) lymph node negative ER+ breast cancers?
What do you do with low grade (grade 1/3) tumors? In other words, does high grade pathology over rules?
Answer from: Medical Oncologist at Academic Institution
No it doesn't overrule. The key question is whether you would predicate chemotherapy use according to the genomic test estimates of prognosis with ET alone (oncotype, mammaprint, prosigna, EPclin etc).
Sign in or Register to read more